RU2009105762A - Макроциклические соединения, применимые в качестве ингибиторов васе - Google Patents
Макроциклические соединения, применимые в качестве ингибиторов васе Download PDFInfo
- Publication number
- RU2009105762A RU2009105762A RU2009105762/04A RU2009105762A RU2009105762A RU 2009105762 A RU2009105762 A RU 2009105762A RU 2009105762/04 A RU2009105762/04 A RU 2009105762/04A RU 2009105762 A RU2009105762 A RU 2009105762A RU 2009105762 A RU2009105762 A RU 2009105762A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- cycloalkyl
- dioxo
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- -1 aryl (C1-C4) alkyl Chemical group 0.000 claims abstract 59
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 14
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 14
- 125000003118 aryl group Chemical group 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 13
- 239000001257 hydrogen Substances 0.000 claims abstract 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000001424 substituent group Chemical group 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 4
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 125000005842 heteroatom Chemical group 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000000926 neurological effect Effects 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- XXOQJWXDRPURJK-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1-benzoxepine Chemical compound O1CCCCC2=CC=CC=C21 XXOQJWXDRPURJK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005529 alkyleneoxy group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000007306 functionalization reaction Methods 0.000 claims 1
- 238000005649 metathesis reaction Methods 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 claims 1
- 239000010937 tungsten Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117571.7 | 2006-07-20 | ||
| EP06117571 | 2006-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009105762A true RU2009105762A (ru) | 2010-08-27 |
Family
ID=37467481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009105762/04A RU2009105762A (ru) | 2006-07-20 | 2007-07-20 | Макроциклические соединения, применимые в качестве ингибиторов васе |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090312370A1 (https=) |
| EP (1) | EP2046761A2 (https=) |
| JP (1) | JP2009544599A (https=) |
| KR (1) | KR20090039726A (https=) |
| CN (1) | CN101490018A (https=) |
| AU (1) | AU2007275067A1 (https=) |
| BR (1) | BRPI0715440A2 (https=) |
| CA (1) | CA2657280A1 (https=) |
| MX (1) | MX2009000710A (https=) |
| RU (1) | RU2009105762A (https=) |
| WO (1) | WO2008009750A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| US20080132477A1 (en) * | 2005-01-13 | 2008-06-05 | Claudia Betschart | Macrocyclic Compounds Useful as Bace Inhibitors |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0526614D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| CA2656869A1 (en) * | 2006-07-20 | 2008-01-24 | Novartis Ag | Macrocyclic lactams |
| CN104619707A (zh) | 2012-07-31 | 2015-05-13 | 协和发酵麒麟株式会社 | 稠环杂环化合物 |
| US20140371283A1 (en) | 2013-02-12 | 2014-12-18 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| CN108732355B (zh) * | 2017-04-25 | 2021-06-25 | 首都医科大学附属北京安定医院 | 一种测定bace1酶切nrg1活性的检测方法及其试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100856A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| US20080132477A1 (en) * | 2005-01-13 | 2008-06-05 | Claudia Betschart | Macrocyclic Compounds Useful as Bace Inhibitors |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0526614D0 (en) * | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| CA2656869A1 (en) * | 2006-07-20 | 2008-01-24 | Novartis Ag | Macrocyclic lactams |
| MX2009000769A (es) * | 2006-07-21 | 2009-01-28 | Novartis Ag | Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak. |
-
2007
- 2007-07-20 JP JP2009519995A patent/JP2009544599A/ja not_active Withdrawn
- 2007-07-20 WO PCT/EP2007/057540 patent/WO2008009750A2/en not_active Ceased
- 2007-07-20 CA CA002657280A patent/CA2657280A1/en not_active Abandoned
- 2007-07-20 MX MX2009000710A patent/MX2009000710A/es unknown
- 2007-07-20 RU RU2009105762/04A patent/RU2009105762A/ru not_active Application Discontinuation
- 2007-07-20 AU AU2007275067A patent/AU2007275067A1/en not_active Abandoned
- 2007-07-20 CN CNA2007800274885A patent/CN101490018A/zh active Pending
- 2007-07-20 BR BRPI0715440-2A patent/BRPI0715440A2/pt not_active Application Discontinuation
- 2007-07-20 KR KR1020097001065A patent/KR20090039726A/ko not_active Withdrawn
- 2007-07-20 EP EP07819910A patent/EP2046761A2/en not_active Withdrawn
- 2007-07-20 US US12/374,467 patent/US20090312370A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009544599A (ja) | 2009-12-17 |
| CN101490018A (zh) | 2009-07-22 |
| KR20090039726A (ko) | 2009-04-22 |
| AU2007275067A1 (en) | 2008-01-24 |
| MX2009000710A (es) | 2009-01-30 |
| WO2008009750A2 (en) | 2008-01-24 |
| EP2046761A2 (en) | 2009-04-15 |
| BRPI0715440A2 (pt) | 2013-07-23 |
| CA2657280A1 (en) | 2008-01-24 |
| US20090312370A1 (en) | 2009-12-17 |
| WO2008009750A3 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009105762A (ru) | Макроциклические соединения, применимые в качестве ингибиторов васе | |
| RU2009105764A (ru) | Макроциклические соединения, применимые в качестве ингибиторов васе | |
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| EA036001B1 (ru) | Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких | |
| RU2006119504A (ru) | Макроциклические лактамы и их фармацевтические применения | |
| RU2008130926A (ru) | Макроциклические соединения для применения в качестве ингибиторов васе | |
| TW201113289A (en) | BACE inhibitors | |
| CA2889378A1 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| KR20160115991A (ko) | Midh1 억제제로서의 벤즈이미다졸-2-아민 | |
| JP2010527983A5 (https=) | ||
| JP5564495B2 (ja) | チアゾリル−およびオキサゾリル−イソキノリノン、ならびにそれらの使用方法 | |
| CA2809256A1 (en) | Compounds for treatment of cancer | |
| WO2008130552A1 (en) | Triazole derivatives which are smo antagonists | |
| JP2009544599A5 (https=) | ||
| FR2673182A1 (fr) | Piperazines n,n'-disubstituees, leur procede de preparation et leur application en therapeutique. | |
| JP2009544597A5 (https=) | ||
| RU2007130794A (ru) | Макроциклические соединения для применения в качестве ингибиторов bace | |
| TWI403320B (zh) | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| KR0165108B1 (ko) | 디벤즈[b,f][1,4]옥사제핀(및 티아제핀)-11(10H)-온 및 -티온을 포함하는 사람 면역 결핍 바이러스(HIV)-1 감염 예방 또는 치료용 약제학적 조성물 | |
| KR20220130761A (ko) | 호흡기 세포융합 바이러스 억제제의 합성 및 사용 | |
| WO2024020333A2 (en) | Kinase inhibitors | |
| RU2007130798A (ru) | Макроциклические соединения и композиции, полезные в качестве ингибиторов васе | |
| TW201144321A (en) | Benzazepine compound | |
| RU2009123532A (ru) | Производные 2-гидрокси-1,3-диаминопропана |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110315 |